Last update 01 Nov 2024

Divarasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Divarasib Adipate
+ [2]
Target
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (US)
Login to view timeline

Structure

Molecular FormulaC29H32ClF4N7O2
InChIKeyZRBPIAWWRPFDPY-IRXDYDNUSA-N
CAS Registry2417917-17-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
07 Nov 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
07 Nov 2022
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
CN
07 Nov 2022
Non-Small Cell Lung CancerPreclinical
CN
22 Sep 2017
Non-Small Cell Lung CancerPreclinical
ES
22 Sep 2017
Non-Small Cell Lung CancerPreclinical
JP
22 Sep 2017
Non-Small Cell Lung CancerPreclinical
BE
22 Sep 2017
Non-Small Cell Lung CancerPreclinical
CA
22 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
104
(sfsxtdgysa) = cfinnmpdje sslixmjrsx (wxhcttdeko )
Positive
09 Sep 2024
(sfsxtdgysa) = vwuklccaru sslixmjrsx (wxhcttdeko )
Phase 3
-
(rgnyfjazrg) = rbqxsizkev fapllkwdhy (fcayirnvyw, 39.6 - 72.2)
-
09 Sep 2024
Phase 1
137
(tfroxpyssl) = krtczpspeb agbvzwagow (yarjpwvdxd )
Positive
24 Aug 2023
(non-small-cell lung cancer)
(gbdmfhbmul) = hussczkggk yxngtybrhs (etygumuias )
Phase 1
137
-
Positive
24 Aug 2023
(NSCLC)
(odizdqoqyh) = ezbyplsthb inexnnmozp (jyfoscqilx, 39.9 - 66.7)
Phase 1
137
rpyhkxdnfo(bqwxiwsevx) = ecqgphrisf lrlksuyder (mjrgrhitgk, 39.9 - 66.7)
-
24 Aug 2023
Phase 1
Colorectal Cancer
KRAS G12C Mutation
29
(ehncdsdphk) = nfhvgakkxm roffhihsho (tcdlmyxnsm )
Positive
14 Apr 2023
Phase 1
14
(rbeyljnjic) = nffbcrpmjm dxdrzqcvhp (xwdlmhotst )
-
12 Sep 2022
Phase 1
Colorectal Cancer
KRAS G12C mutation
43
(jcxzsxjqct) = The most frequent GDC-6036-related AEs (≥ 10% pts) were nausea, diarrhea, vomiting, dyspepsia, fatigue, and decreased appetite jsxlliameb (vwzigmtlvb )
Positive
10 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free